* Passage Bio Inc PASG.OQ PASG.O is expected to show no
change
in quarterly revenue when it reports results on November 10.
*
* Refinitiv's mean analyst estimate for Passage Bio Inc is
for a
loss of 79 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Passage Bio
Inc
is $9, above its last closing price of $1.20.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.79 -0.83 -0.73 Beat 11.7
Mar. 31 2022 -0.91 -0.89 -0.79 Beat 11
Dec. 31 2021 -0.90 -0.89 -0.95 Missed -7.2
Sep. 30 2021 -0.89 -0.86 -0.87 Missed -1
Jun. -0.76 -0.76 -0.90 Missed -18.9
30 2021
Mar. 31 2021 -0.75 -0.74 -0.76 Missed -2.2
Dec. 31 2020 -0.69 -0.70 -0.85 Missed -21
Sep. 30 2020 -0.78 -0.76 -0.63 Beat 17.1
This summary was machine generated November 8 at 19:32 GMT. All
figures in US dollars unless otherwise stated